← Back to Screener
Citius Oncology, Inc. Common Stock (CTOR)
Price$0.81
Favorite Metrics
Price vs S&P 500 (26W)-58.88%
Price vs S&P 500 (4W)15.88%
Market Capitalization$73.27M
All Metrics
Book Value / Share (Quarterly)$0.69
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.15
Price vs S&P 500 (YTD)-19.64%
EPS (TTM)$-0.31
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-0.31
EPS (Annual)$-0.34
ROI (Annual)-50.88%
Cash / Share (Quarterly)$0.09
ROA (Last FY)-24.53%
EBITD / Share (TTM)$-0.28
Cash Flow / Share (Annual)$-0.07
P/B Ratio1.25x
P/B Ratio (Quarterly)1.45x
Net Interest Coverage (TTM)-129.49x
ROA (TTM)-23.99%
EPS Incl Extra (Annual)$-0.34
Current Ratio (Annual)0.56x
Quick Ratio (Quarterly)0.25x
3-Month Avg Trading Volume0.35M
52-Week Price Return25.00%
52-Week High$6.19
EPS Excl Extra (Annual)$-0.34
26-Week Price Return-54.89%
Quick Ratio (Annual)0.08x
13-Week Price Return-22.43%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)0.83x
Enterprise Value$69.773
Cash / Share (Annual)$0.05
3-Month Return Std Dev86.12%
ROE (Last FY)-55.19%
EPS Basic Excl Extra (Annual)$-0.34
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-0.31
ROI (TTM)-50.69%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-4.83%
Year-to-Date Return-17.00%
5-Day Price Return25.76%
EPS Normalized (Annual)$-0.34
Month-to-Date Return33.87%
EBITD / Share (Annual)$-0.32
LT Debt / Equity (Annual)0.08x
LT Debt / Equity (Quarterly)0.07x
EPS Basic Excl Extra (TTM)$-0.31
P/B Ratio (Annual)3.78x
Book Value / Share (Annual)$0.54
Price vs S&P 500 (13W)-23.12%
Beta3.50x
P/FCF (Annual)579.88x
Revenue / Share (TTM)$0.05
ROE (TTM)-55.19%
52-Week Low$0.49
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CTORCitius Oncology, Inc. Common Stock | — | — | — | — | $0.81 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Citius Oncology is a biopharmaceutical company developing targeted cancer therapies through lower-risk approaches, including new formulations and expanded indications for approved drugs. The company leverages intellectual property and regulatory exclusivity to accelerate market entry while serving key cancer centers.